Prognostic Implications of Widespread FDG Uptake in Spleen and/or Bone Marrow Linked to Reticuloendothelial System Activation in Patients with Lymphoma - Report - MDSpire
Advertisement
Prognostic Implications of Widespread FDG Uptake in Spleen and/or Bone Marrow Linked to Reticuloendothelial System Activation in Patients with Lymphoma
Prognostic Implications of Widespread FDG Uptake in Spleen and Bone Marrow
Overview
Expand to include specific mechanisms linking FDG uptake to systemic inflammation and its predictive value.
Background
Lymphoma is a malignant disorder with increasing global incidence and complex clinical manifestations. Accurate prognostic assessment is crucial for individualized treatment, especially in advanced cases with systemic involvement. Functional imaging, particularly ¹⁸F-FDG PET/CT, is essential for evaluating disease burden and treatment response, yet the implications of diffuse FDG uptake in the spleen and bone marrow remain unclear.
Data Highlights
Replace with relevant data or a clear statement about the absence of specific numerical data.
Key Findings
Diffuse FDG uptake in the spleen and bone marrow may indicate heightened systemic inflammation.
Elevated spleen-to-liver standardized uptake ratio (SLR) correlates with poor progression-free survival in lymphoma.
Diffuse uptake in these organs can serve as surrogate indicators of systemic inflammatory activity.
Prior studies show that systemic inflammation markers are linked to aggressive lymphoma behavior and poor survival.
Focal FDG uptake is associated with true marrow involvement, while diffuse uptake often reflects reactive changes.
Clinical Implications
Clinicians should consider diffuse FDG uptake in the spleen and bone marrow as potential indicators of systemic inflammation in lymphoma patients. This may enhance prognostic stratification and inform treatment decisions, particularly in advanced disease stages.
Conclusion
The study highlights the importance of evaluating diffuse FDG uptake in the spleen and bone marrow as a prognostic tool in lymphoma, potentially guiding individualized treatment strategies.
Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.
Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.
